Completed

Thymopentin's Effect on HIV-1 Infection and Immune System Stimulation

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Thymopentin

Drug
Who is being recruted

Blood-Borne Infections+13

+ Urogenital Diseases

+ Genital Diseases

Over 18 Years
+14 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
See protocol details

Summary

Principal SponsorImmunobiology Research Institute
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

This study looks into the potential of a drug called thymopentin, also known as Timunox, to help individuals infected with HIV-1. The main goal is to see if this drug can decrease the amount and frequency of the virus detected. Additionally, the study aims to find out if thymopentin can boost the immune system and change the clinical results in HIV patients who have not yet developed AIDS. This research is crucial as it could pave the way for new treatment options for HIV patients, potentially improving their quality of life and slowing disease progression.

NCT00002066
Principal SponsorImmunobiology Research Institute
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeHIV Infections

Criteria

5 inclusion criteria required to participate
Patients with HIV "wasting syndrome" are included.
Patient must voluntarily sign consent and be seropositive for HIV-1 (ELISA assay) confirmed by Western blot.
Allowed: Aerosolized pentamidine. (Concurrent Medication)
Allowed: Aerosolized pentamidine. (Prior Medication)
Show More Criteria
9 exclusion criteria prevent from participating
Excluded within 90 days of study entry: Zidovudine (AZT). (Prior Medication)
Excluded within 90 days of study entry: Zidovudine (AZT). (Concurrent Medication)
Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products.
Thrombocytopenia (< 75000 platelets/mm3).
Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Immunobiology Research Institute

Annandale, United StatesOpen Immunobiology Research Institute in Google Maps
CompletedOne Study Center